Abeona therapeutics activates second clinical trial site in eb-101 pivotal phase 3 viital™ study for recessive dystrophic epidermolysis bullosa

New york and cleveland, july 23, 2021 (globe newswire) -- abeona therapeutics inc. (nasdaq: abeo), a fully-integrated leader in gene and cell therapy, today announced the activation of a second clinical trial site in its pivotal phase 3 viital™ study of its investigational eb-101 treatment for recessive dystrophic epidermolysis bullosa (rdeb) at umass memorial medical center in worcester, ma.
ABEO Ratings Summary
ABEO Quant Ranking